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COMPARISON OF TRANEXAMIC ACID AND
AMINOCAPROIC ACID IN CORONARY BYPASS SURGERY
LISA K. LECLEIR, BUTLER UNIVERSITY
MENTOR: CHAD KNODERER
Abstract
OBJECTIVE: Tranexamic acid (TXA) and ɛ-aminocaproic acid (EACA) are
used in coronary bypass surgery for anti-fibrinolytic therapy. Since the
removal of aprotinin, data directly comparing their blood sparing effect and
their side effects is still missing.
METHODS: Fifty patients undergoing coronary bypass cardiac surgery at a
community teaching hospital were evaluated in a retrospective cohort study.
Perioperative data was collected by a thorough chart review.
Patients
received EACA from 01/01/2013 to 04/05/2013 or TXA from 05/07/2013 to
12/31/2013. Primary outcome was the amount of chest tube output
throughout the hospital stay. Secondary outcomes were the amount of blood
transfusion requirements, post-operative complications, number of ICU days,
need for re-exploration, and in-hospital mortality.
RESULTS: All demographic and pre-operative parameters were well
comparable for patients who received EACA (n = 25) and those who received
TXA (n = 25). There was no difference in chest tube output (EACA 942 ± 371
mL vs. TXA 1162 ± 480 mL, p = 0.077). There were also not any differences in
blood transfusion requirements (EACA 4.92 ± 3.29 units vs. TXA 3.44 ± 2.10
units, p = 0.064), nor in post-operative complications such as atrial
fibrillation, unstable blood pressure, pneumonia, or pleural effusions related
to surgery (EACA 20% vs. TXA 32%, p = 0.520). There were not any patients
in the study who experienced a need for re-exploration or in-hospital
mortality. The number of days spent in the ICU (EACA 1.60 ± 1.35 vs. TXA
1.08 ± 0.4, p = 0.0717) were also found to be statistically non-significant.
CONCLUSIONS: TXA and EACA are comparable in the effect of chest tube
output and blood transfusion requirements, as well as their adverse event
profile. Although the number of days spent in the ICU approached statistical
significance for favoring TXA, either agent would be appropriate to be
utilized in coronary bypass cardiac surgery.
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Background
Cardiopulmonary bypass (CPB), or the ‘heart-lung machine,’ is an essential
part of cardiac surgery. It allows the blood to be oxygenated and dissipates
carbon dioxide while the heart and lungs are at rest. In order for CPB to be
fully safe and effective, reversible anticoagulation must be used and the blood
must be pumped without destruction of red blood cells or other blood
components.1 To achieve this, the patient is systemically heparinized and the
CPB components are heparin coated.2 Although protamine can be utilized to
reverse the effects of heparin, cardiac surgery patients are still at an
increased bleeding risk.3,4,5 Up to 10% of cardiac surgery patients experience
massive blood loss after CPB. Massive blood loss is defined as chest tube
bleeding >2 L up to 24 hours post-operatives, ≥10 units of packed red blood
cells (RBC) transfused, or bleeding requiring a re-exploration surgery. This
coagulopathy related to CPB is multifactorial by alterations in the
coagulation cascade, inflammatory processes, and fibrinolysis.3
During CPB, the coagulation cascade is altered by heparin and antiplatelet use. CPB also requires hemodilution of the blood volume which
results in decreased numbers of coagulation factors and causes platelet
dysfunction. When activated, certain coagulation factors are proinflammatory, such as factor Xa and thrombin. The resultant inflammation
can ultimately cause end-organ damage, such as renal dysfunction. For
adequate clot formation after CPB, fibrinogen levels should be maintained at
≥200 mg/dL. Fibrinolysis can occur as a result of decreased levels of
fibrinogen and the release of endogenous fibrinolytics. Endogenous
fibrinolytics, such as urokinase and tissue plasminogen activator (tPA), can
split fibrin and fibrinogen into inactive segments. These inactive segments
are called D dimers, and they have no coagulation activity.3 To manage
perioperative bleeding from the CPB-related coagulopathy, various
medications are given prophylactically. Fibrinogen concentrate can be given
to increase fibrinogen levels.6 Also, anti-fibrinolytics, such as aminocaproic
acid (EACA)7 and tranexamic acid (TXA)8 , are given in the majority of cardiac
surgeries that use CPB. Anti-fibrinolytics are utilized to diminish the effects
of endogenous fibrinolytics which are released in response to CPB-related
coagulopathy.4
CPB-related coagulopathy greatly increases the bleeding risk in
patients. Anti-fibrinolytics are used preoperatively to minimize the incidence
of postoperative bleeding, but no head-to-head trials exist to compare TXA
and EACA. Both medications came to market based on non-inferiority studies
to aprotinin, which was pulled from the market due to post-marketing safety
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studies. Increased bleeding can increase the patient’s mortality, increase the
hospital length of stay, and increase the amount of hospital resources
utilized.3 The Society of Thoracic Surgeons and Society of Cardiovascular
Anesthesiologists currently recommend anti-fibrinolytics to be a Class I, level
of evidence A guideline recommendation for them to be used in perioperative
blood conservation in cardiac surgery.4
The objective of this study is to evaluate the difference between EACA
and TXA in cardiac bypass surgery. If a difference is shown preferring either
agent in blood conservation, an argument will be able to be made to utilize
this agent preferably in an effort to decrease other hospital costs and
conserve the blood bank.
Methods
Based on previous non-inferiority studies of EACA and TXA to aprotinin, a
power of fifty patients was found to be adequate for this study. Inclusion
criteria were any patient undergoing coronary bypass cardiac surgery at a
community teaching hospital from 4/6/2013 to 5/6/2013. Exclusion criteria
were any patient who was pregnant or under 18 years of age. This month
duration was the transition period of switching medications and there was
the possibility of prescriber bias for which patient received either medication.
In this retrospective cohort study, patients were randomly selected until
there were twenty-five patients who had received TXA and twenty-five
patients who had received EACA. Primary outcome was the amount of chest
tube output throughout the hospital stay. Secondary outcomes were the
amount of blood transfusion requirements, post-operative complications,
number of ICU days, need for re-exploration, and in-hospital mortality.
Patients were identified by billing records for EACA or TXA during
2013. Perioperative data was collected by a chart review conducted by the
secondary investigators. Baseline characteristics collected were age, gender,
race, weight, smoker status, and past medical history. Past medical history
included chronic hypertension, type 2 diabetes mellitus, history of
arrhythmia, previous MI, previous thromboembolic event, number of prior
surgeries. All surgeries were included, with the exception of orthopedic,
ophthalmic, or otorhinolaryngologic interventions. Medications accounted for
at baseline included aspirin, clopidogrel, and anticoagulation use. Preoperative laboratory values evaluated were serum creatinine (SCr), estimated
creatinine clearance (CrCl), hemoglobin (Hgb), hematocrit (Hct), activated
partial thromboplastin time (aPTT), prothrombin time (PT), fibrinogen, and
international normalized ratio (INR). Patient confidentiality was ensured by
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maintaining information on an encrypted jump drive and will not be
destroyed for two years after data collection. IRB approval was granted from
the community teaching hospital and the affiliated university. As a
retrospective cohort study, there were no ethical or safety issues in
completing this study.
Demographic characteristics and all categorical data points were
evaluated by a Fischer’s exact test with a two-tailed p value. Fischer’s exact
test was chosen over the chi-square test, due to some demographic
characteristics, such as race or past medical history, which had numerical
values less than five. Continuous data points, such as laboratory values, were
evaluated by an unpaired t-test with a two-tailed p value. The unpaired t-test
was chosen over the paired t-test, due to nature of the study comparing two
independent patient groups. Alpha was set at 0.05. Due to the lack of postoperative laboratories that were evaluated, this was not included as a data
collection endpoint. The specific dosing regimen for each patient was unable
to be acquired; however, the collective amount of EACA or TXA billed to the
patient was included in the original patient identification process.
Results
Patients received EACA from 01/01/2013 to 04/05/2013 or TXA from
05/07/2013 to 12/31/2013. There were not any patients evaluated that met the
exclusion criteria. All demographic and pre-operative parameters were well
comparable (Tables 1 and 2).
All patients underwent a coronary artery bypass graft due to coronary
atherosclerosis. Each patient’s antiplatelet therapy (aspirin, clopidogrel) was
held for 24 hours prior to surgery, if applicable. During the surgery, each
patient was systemically heparinized and was given EACA or TXA according
to the dosing protocols.
There was no difference in the primary outcome of chest tube output
(EACA 942 ± 371 mL vs. TXA 1162 ± 480 mL, p = 0.077). See Figure 1.
There were also not any differences in blood transfusion requirements (EACA
4.92 ± 3.29 units vs. TXA 3.44 ± 2.10 units, p = 0.064), nor in the amount of
patients who required platelets, fresh frozen plasma, cryoprecipitate, factor
VII, or prothrombin complex concentrate (EACA 28% vs. TXA 24%, p =
1.000). Also, post-operative complications such as atrial fibrillation, unstable
blood pressure, pneumonia, or pleural effusions related to surgery (EACA
20% vs. TXA 32%, p = 0.520) were not found to be statistically significant.
There were not any patients in the study who experienced a need for reexploration or in-hospital mortality. Finally, the number of days spent in the
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ICU (EACA 1.60 ± 1.35 vs. TXA 1.08 ± 0.4, p = 0.0717) were also not found to
be statistically significant.

Table 1. EACA & TXA demographic parameters.
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Table 2. EACA & TXA pre-operative parameters.

Figure 1. Primary outcome of chest tube output.

!112

Discussion
Patients received EACA from 01/01/2013 to 04/05/2013 or TXA from
05/07/2013 to 12/31/2013. There were not any patients evaluated that met
There have been three anti-fibrinolytics that have been on the market:
aprotinin, EACA, and TXA. Aprotinin is a peptide serine protease inhibitor
that inhibits fibrinolysis and affects the inflammatory process. Aprotinin was
consistently shown to be efficacious in decreasing the need for transfusions.
However, in two large observational studies it was shown to have an
increased mortality rate and increased serum creatinine levels leading to
kidney injury. Therefore, aprotinin was removed from market in November
2007.3-4
The other two anti-fibrinolytics are lysine analogs: EACA and TXA.
These medications compete with fibrin for binding sites which then inhibits
the conversion from plasminogen to plasmin. The dosing of these medications
typically includes a CPB priming dose, loading dose, and maintenance dose.
Various dosing regimens have been utilized. There are multiple ways to dose
EACA and TXA. At the community hospital studied, EACA is dosed as 5-10
grams loading dose, then 1-2.5 grams/hr maintenance dose, until the end of
the operation. On average, this calculates out to a 75 mg/kg loading dose,
then a 10-15 mg/kg/hr until the end of the surgery. For TXA, a 2mg/kg CPB
prime, 30 mg/kg load, and 16 mg/kg/hr maintenance dose was utilized.3 As for
the efficacy, the studies to date are done in comparison to aprotinin and both
have been found to be alternatives to aprotinin.
In 2001, a randomized, double-blind, placebo-controlled, noninferiority trial was completed comparing EACA and aprotinin in 81 patients
undergoing CABG with CPB. EACA was shown to be non-inferior to
aprotinin by the surrogate marker of D-dimer formation for fibrinolysis
reduction and the endpoint of blood loss measured by 24-hour chest tube
drainage. For D dimer formation, the results were: aprotinin 608 ± 279 µg/L
vs EACA 612 ± 335 µg/L (difference -3.58 µg/L, 95% CI -203 to 195 µg/L). For
the amount of chest tube drainage, the results were: aprotinin 685 ± 505 mL
vs. EACA 715 ± 394 mL (difference 67 mL, 95% CI -90 to 230 mL).9 Both the
surrogate marker of D dimer formation and endpoint of chest tube drainage
was a non-significant difference between aprotinin and EACA. This shows
that EACA is noninferior to aprotinin and can therefore be utilized as an
alternative in patients undergoing CABG with CPB.
In 2004, a randomized, double-blind, prospective trial was completed
comparing TXA and aprotinin in 118 patients undergoing CABG with CPB.
TXA was shown be an alternative to aprotinin by the end points of total blood
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loss and transfusion requirements. For total blood loss, the results were:
aprotinin 756 mL ± 347 vs TXA 896 mL ± 354, p = 0.03. For RBC transfusion,
the results were: aprotinin 1.5 units ± 1.7 vs. TXA 1.5 units ± 1.5, p = 1.0.
The blood loss was concerning because the difference was found to be
statistically significant; however, the transfusion requirements for both
aprotinin and TXA patients were shown to be statistically insignificant.10
In this retrospective cohort study at a community teaching hospital of
fifty patients, EACA and TXA were not found to be statistically different.
Both are comparable for efficacy in regards to the amount of chest tube
output, blood transfusion requirements, and amount of days spent in the
ICU. Since the p value for the amount of days spent in the ICU approached
statistical significance in favor of TXA, a future study with a larger sample
population and greater power is warranted. The tolerability of EACA and
TXA was shown to be similar, due to the lack of difference in re-exploration
rates, mortality, or adverse effects.
As a retrospective cohort study, the ability for controlling confounding
variables through non-statistical approaches is limited. One limitation to the
data collection process is the lack of selection randomization. The
investigators did randomly select patients, but this process was not
formalized. Although a sample of fifty patients was found to be adequate for
this study, the wide variation in standard deviation indicates that a type II
error may have occurred. The comparable patient characteristics preoperatively benefited this study and increased its validity.
Conclusion
EACA and TXA are comparable in the amount of chest tube output and blood
transfusion requirements, as well as their adverse outcomes. A future study
with a greater sample population could increase the power of this
retrospective cohort study. Although the number of days spent in the ICU
approached statistical significance for favoring TXA, either agent would be
appropriate to be utilized in coronary bypass surgery.
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